Phase 3 data show lebrikizumab improves skin clearance and itch in children with moderate to severe atopic dermatitis, ...

Patients with multiple sclerosis (MS) who were receiving disease-modifying therapies were found to have rare occurrences of severe COVID-19 if they had received the vaccine, according to a study ...

Vutrisiran kept a favorable safety profile in patients with transthyretin amyloidosis treated for up to 58 months, with AE rates comparable to placebo and no new safety concerns.

The FDA has approved secukinumab (Cosentyx; Novartis) for the treatment of pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), the company announced. 1 The ...

Plan sponsors are able to dispute a PBM’s plan if it’s not reasonable or relevant, directly through CMS. Should PBMs refuse to provide 100% pass-through, the contract will no longer be reasonable.

In an interview with the American Journal of Managed Care®, Greenspan explained why oxygen therapy is beneficial for patients ...

A BTK inhibitor combined with standard R-CHOP produced rapid, PET-defined complete remission in high-risk DLBCL-type Richter syndrome with TP53 deletion. Delaying ibrutinib until cycle 2 was used as a ...

Rebecca L. Siegel, MPH, lead author of the “Colorectal Cancer Statistics, 2026” report recently published in CA: A Cancer ...

CMMI’s agenda centers on productivity and value-based payment expansion, including outcomes-based reimbursement, Most-Favored ...

Peter Staley at CROI 2026 on defending 45 years of HIV progress: how clinicians, payers, and advocates can resist—quietly or publicly—and why it matters.

GPT-4o achieved ICC/CCC of 0.815/0.866 versus in-person SALT scoring and 0.833/0.817 versus image-based scoring, while expert ...

At the Winter Clinical Dermatology Meeting, April W. Armstrong, MD, MPH, professor and chief of dermatology at the UCLA ...